Natixis Advisors
AVNS

Natixis Advisors’s Avanos Medical AVNS Stock Holding History

Natixis Advisors’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$260K Buy
+10,482
New +$245K ﹤0.01% 1797
2025
Q4 		– Sell
-20,903
Closed -$242K – 1603
2025
Q3 		$242K Sell
20,903
-31,984
-60% -$375K ﹤0.01% 1608
2025
Q2 		$647K Buy
52,887
+33,163
+168% +$417K ﹤0.01% 1421
2025
Q1 		$283K Sell
19,724
-6,220
-24% -$97.1K ﹤0.01% 1558
2024
Q4 		$413K Buy
25,944
+4,492
+21% +$88.9K ﹤0.01% 1509
2024
Q3 		$515K Buy
21,452
+2,574
+14% +$58.8K ﹤0.01% 1448
2024
Q2 		$376K Buy
18,878
+3,077
+19% +$59.9K ﹤0.01% 1484
2024
Q1 		$315K Buy
15,801
+1,659
+12% +$32.1K ﹤0.01% 1470
2023
Q4 		$317K Buy
+14,142
New +$292K ﹤0.01% 1458
2023
Q3 		– Sell
-18,217
Closed -$466K – 1487
2023
Q2 		$466K Buy
18,217
+2,877
+19% +$75.8K ﹤0.01% 1353
2023
Q1 		$456K Buy
15,340
+1,721
+13% +$50K ﹤0.01% 1327
2022
Q4 		$369K Buy
+13,619
New +$333K ﹤0.01% 1361
2022
Q2 		– Sell
-11,287
Closed -$378K – 1457
2022
Q1 		$378K Buy
+11,287
New +$364K ﹤0.01% 1333

Other funds holding AVNS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.5B AUM 83.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Natixis Advisors's AVNS Position: Q2 2026 in Review

Natixis Advisors opened a new position in Avanos Medical (AVNS) in Q2 2026: 10,482 shares worth $260K. The stake represents ﹤0.01% of the portfolio and ranks #1797 among its holdings. This is a return to the name: Natixis Advisors previously reported a position in AVNS as recently as Q3 2025.

Natixis Advisors first reported a position in AVNS in Q1 2022 and has held it in 13 quarters since. The position peaked at $647K in Q2 2025. 286 funds tracked by Wall St. Rank hold AVNS as of Q2 2026.

  • Natixis Advisors held 10,482 shares of Avanos Medical worth $260K as of Q2 2026.
  • Avanos Medical was a new Natixis Advisors position in Q2 2026.
  • Avanos Medical made up ﹤0.01% of Natixis Advisors's portfolio in Q2 2026, its #1797 holding.
  • Natixis Advisors first reported a position in Avanos Medical in Q1 2022 and has held it in 13 quarters since.
  • Natixis Advisors's Avanos Medical position peaked at $647K in Q2 2025.
  • 286 funds tracked by Wall St. Rank held Avanos Medical as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.